The following is the agenda for ChinaBio Investor Forum 2012-Beijing.
(Updated on August 24, 2012)
®
ChinaBio Investor Forum 2012-Beijing - Detailed Agenda
17:30 19:30
Time
08:00 09:00
Tuesday, September 4, 2012
Welcome Reception
Meet with speakers and other attendees at
this informal reception
Day 1 - Wednesday, September 5, 2012
Title/Description
Speakers
Registration and Refreshments
Greg B. Scott - President &
Founder, ChinaBio LLC
Jiantao He - Vice Director,
Daxing Bio-medicine Industry
Park
Marko Vänskä - CEO,
China-Finland Golden Bridge
®
09:00 09:30
Welcome Remarks
Keynote 1: The State of China Life
Science: From Local to Global
09:30 10:00
As China's life science industry continues
to lead the world in growth, it is quickly
evolving from a local market to having
global impact. Innovation is now being
created inside of China at the same time
international companies are bringing
innovation to China. This has stimulated
VC investment, M&A and IPO activity in
China, and driven partnering and
corporate investment to new heights. Mr.
Scott will present recent data on the
industry, highlighting areas of significant
opportunity in China.
Greg B. Scott - President &
Founder, ChinaBio LLC
®
Keynote 2: BioFinland Investment
Opportunities
10:00 10:30
10:30 11:00
A strong combination of science and
technological expertise makes Finland one
of the most competitive nations in the
world in biotechnology and healthcare.
Kalevi Reijonen, PhD - Board
Finnish life science companies are now
Member, Finnish Biotech
entering the Chinese market and investors Association
are seeking leading technologies to bring
to China, making a good match. Dr.
Reijonen will provide insights on the
biotech industry and innovation in Finland,
and which technology trends Chinese
investors should keep their eye on.
Networking Break and Refreshments
Moderator:
James F. Ewing, JD, PhD Partner, Foley & Lardner LLP
Panelists:
While the US and Europe are facing a
Min Cui, PhD - Managing
significant drought in funding available for Director, Decheng Capital
life science companies, VC funding in
Karen Liu, PhD, EMBA China remains alive and well. Many
Partner, Kaiwu Capital
international as well as domestic
Yi Shi, PhD, MBA - Managing
investment firms are seeking mid- and
Director, Lilly Asian Ventures
late-stage investments as well as early
Xiangyu Ouyang, EMBA stage companies offering novel
Managing Director, Legend
technologies addressing significant
Capital
markets. Hear from a group of seasoned
Jonathan Wang, PhD, MBA VCs managing major funds focused on the
Senior Managing Director,
China life science industry.
OrbiMed
Panel 1: VC Funding in China: Alive
and Well
11:00 12:00
12:00 13:30
13:30 15:00
15:00 17:00
17:00 18:30
Luncheon
Finnish Company Presentations
VC Breakout Meetings
Beijing Daxing Life Science Park Tour
Daxing is a prime location for life science
companies in China, offering a variety of
incentives and support services.
18:30 20:30
Time
08:30 09:30
09:30 10:30
10:30 11:00
Gala Banquet
Join us at the beautiful Roaring Dragon
Pavilion for a dinner fit for the royal family
of the Qing Dynasty.
Day 2 - Thursday, September 6, 2012
Title/Description
Speakers
Registration and Refreshments
Moderator:
Sherry Yin - Partner, Morrison &
Panel 2: Alternative Funding:
Foerster LLP
Corporate Partnering
Panelists:
Lily Han, PhD, MBA - Deputy
Some attractive alternatives to VC money
General Manager of International
include government and corporate
Department, Shanghai Fosun
funding. Corporate partnering and
Pharmaceutical (Group) Co.,
investment are increasing rapidly in China,
Ltd.
with more deals done in 2011 than ever
Sammy Jiang, MBA - Associate
before. Especially in the pharmaceutical
President, Luye Pharma Group
industry, Chinese companies are seeking
Ltd.
to build novel product portfolios through
Larry Liu - Director, Business
in-licensing, co-development, strategic
Development Department,
partnerships and equity investments.
Beijing Hanmi pharmaceutical
Learn what some of China's most
Mike Liu, PhD, MBA - Head of
successful companies are looking for in
Global Business Development,
partnerships.
Jiangsu Hengrui Medicine Co.,
Ltd.
Networking Break and Refreshments
Panel 3: How to Launch a Company in
China
11:00 12:00
12:00 13:30
There are many factors to be considered
when establishing a successful company
in China: corporate structure, location,
intellectual property, government
relationships, VC funding, and more. This
session will guide entrepreneurs in the
best way to leverage the many benefits
China can offer: funding, government
incentives, talent pool, etc.
Luncheon
Greg B. Scott - President &
Founder, ChinaBio LLC
®
13:30 15:00
15:00 16:00
16:00 16:30
16:30 17:00
17:00 18:00
Company Presentations
VC Breakout Meetings
Raffle Drawings - Win valuable prizes
(Must be present to win)
Award Ceremony / Closing Remarks
Closing Reception
The following industry experts will provide insights into China's emerging
biotechnology industry and how to launch and build a successful life science
companies at the ChinaBio Investor Forum 2012 - Beijing.
®














Min Cui, PhD - Managing Director, Decheng Capital
Lily Han, PhD, MBA - Deputy General Manager of International
Department, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Jiantao He, PhD - Vice Director, Daxing Bio-medicine Industry Park
Sammy Jiang, MBA - Associate President, Luye Pharma Group Ltd.
Larry Liu - Director, Business Development Department, Beijing
Hanmi pharmaceutical
Mike Liu, PhD, MBA - Head of Global Business Development,
Jiangsu Hengrui Medicine Co., Ltd.
Karen Liu, PhD, EMBA - Partner, Kaiwu Capital
Xiangyu Ouyang, EMBA - Managing Director, Legend Capital
Kalevi Reijonen, PhD - Board Member, Finnish Biotech Association
Yi Shi, PhD, MBA - Managing Director, Lilly Asian Ventures
Greg Scott - President & CEO, ChinaBio LLC
Marko Vänskä - CEO, China-Finland Golden Bridge
Jonathan Wang, PhD, MBA - Senior Managing Director, OrbiMed
Sherry Yin - Partner, Morrison & Foerster LLP
®
Presenting Companies
The following 18 companies will present at ChinaBio Investor Forum 2012 Beijing.
Register now and join ChinaBio Messaging System (CBMS) to see these
companies' profiles.
®
®
Company/Presenter
ArcDia International Ltd.
(Finland)
Aleksi Soini, PhD - CEO &
President
Ascepion Pharmaceuticals,
Inc.
(Suzhou)
Shan Jiang, PhD - CEO &
Founder
ASLAN Pharmaceuticals
(Singapore)
Carl Firth, PhD, EMBA - CEO &
Founder
BeiGene
(Beijing)
John Oyler, MBA - CEO &
Founder
Beijing T&J Biomedical R&D
Co., Ltd.
(USA/China)
Guohua Yue, PhD - General
Manager
Dragonfly Sciences (Shanghai)
Co., Ltd.
(USA/China)
Jay Zhang, PhD - General
Manager
Ductor Corp.
(Finland)
Jukka Ropponen - COO
FIT Biotech Oy
(Finland)
Kalevi Reijonen, PhD - CEO &
President
GCA Therapeutics Ltd
(USA)
Tina Yu, PhD, MBA - President
Category
Description
A company for R&D, sales and
marketing of innovative products
Diagnostics
for point-of-care testing of
infectious diseases
Drugs
A company dedicated to the
discovery and development of
breakthrough small molecule
cancer drugs
Drugs
Developer of novel medicines for
global markets
Drugs
A company focused on
discovering and developing
innovative oncology drugs
A biotechnological company
developing innovative
Drugs
protein-based drugs, especially
bio-betters, to meet strong
demand in Chinese population
A company focused on the
development of high quality
Drugs
biosimilar drugs of monoclonal
antibodies for inflammation,
autoimmunity and cancer
A company with patented
Technology technology to produce ammonia
Platform
and phosphates biologically from
recycled materials
Drugs
A company with an unique
proprietary platform technology,
Gene Transport Unit, GTU
®
Drugs
A company in-licensing Chinese
rights to proprietary western
pharmaceutical products and
developing them for the Chinese
market
GenePharma
(Suzhou)
Peter Zhang, PhD - CEO &
Chairman
Labrox Ltd
(Finland)
Ida Erling - CEO
Drugs
Provider of siRNA/miRNA related
products and RNAi technology
services, developer of RNAi drugs
and gene diagnostic regents
Devices
Developer and manufacturer of
plate readers for OEM purposes
A company focused on the
diagnosis, treatment and
Diagnostics
prevention of Multiple Organ
Failure
Mylab Healthcare Technology
Leading diagnostic information
Co., Ltd.
service
Services
(Finland/China)
provider for healthcare
Eddie Ma, MBA - CEO
organizations
Nanjing Allgen Pharma Co.
A company focued on novel drugs
(Nanjing)
Drugs
that treat various forms of cancer
Zhaoyin Wang, PhD - President
and inflammatory diseases.
Manufactures digital medical
Optomed Oy
cameras that provide
(Finland/Philippines/China)
Devices
ophthalmoscopic, otoscopic
Xia Jiang - Country Manager
and dermatoscopic imaging with
one hand-held device
Ozics
Revolutionising the management
(Finland)
Medical
of osteoporosis through
Auvo Kaikkonen, MD, PhD Devices
innovative material science and
CEO & President
device design
RemoteA Ltd
Enables diagnosis in the first
(Finland)
Diagnostics point of care and faster access to
Timo Hakkarainen, MBA treatment
Managing Director
Tianjin Rx Pharma Tech Inc.
(Tianjin)
A company aims to develop niche
Drugs
Peter Chen, PhD - Founder &
generic drug products
President
Leading BioSciences, Inc.
(USA)
Hank Loy - President